This case study (n=1) finds that a single low dose of 5 µg (0.38µg/kg) of 1cp-LSD on a 13-year-old female dog with a history of separation-related behavioural problems significantly reduced anxiety after two hours. No adverse effects or signs of a psychedelic experience were observed during the 5.5-hour trial.
Anxiety affects 14-20% of dogs. Pharmacological treatments often fail. Psychedelics have shown to be useful for anxiety and depression in humans, but their veterinary use remains unexplored. We aimed to determine the effects of low-dose 1-cyclopropionyl-d-lysergic acid diethylamide (1cp-LSD) administered in a single dose to a dog, to observe the effect and establish the safety of the substance. The patient was a 13-year-old female dog, weighing 13 kg, mixed breed, and spayed. A total of 5 µg was administered orally, equivalent to 0.38 µg/kg. The animal has had a history of separation related behavioral problems throughout her life. To objectively assess the degree of anxiety in the dog, a validated scale was utilized. The trial was scheduled at the house where the animal lives. The owner was present throughout the experience. Informed consent was obtained prior to the assay. The trial began at 12:15 p.m. on January 10, 2024, lasting for 5 and a half hours. The response to anxiety-inducing stimuli was equally anxious during the first two hours. From that point onwards, a significant change in the animal’s behavior was observed, with no signs/mild signs of anxiety. The trial concluded without any adverse effects on the animal. The patient did not show signs of having a psychedelic experience. This is the first time that a study of this nature has been conducted and reported in the canine species. 1cp-LSD proved to be safe and exerted the desired effect on the animal’s behavior, significantly reducing the patient’s anxiety.
Anxiety affects an estimated 14–20% of domestic dogs and is commonly managed with medications such as selective serotonin reuptake inhibitors, benzodiazepines, tricyclics or alpha-2 agonists, often alongside behavioural support. According to the extracted text, these pharmacological options frequently have limited efficacy, require chronic use, and carry safety or dependency concerns, motivating the search for safer alternatives. In parallel, psychedelics have re-emerged in human psychiatric research for anxiety and depression, and preclinical work suggests that low or “micro” doses of classical psychedelics can produce anxiolytic and antidepressant effects in rodents without overt psychedelic phenomenology. Henríquez-Hernández and colleagues set out to explore whether a single microdose of 1-cyclopropionyl-d-lysergic acid diethylamide (1cP-LSD), a legal LSD analogue and putative prodrug of LSD, is safe in a dog and whether it produces measurable reductions in anxiety. Because no prior controlled studies in canines were reported, the aim was explicitly exploratory: to document behavioural responses and safety after one oral 5 µg dose (approximately 0.38 µg/kg for the subject) and to establish a preliminary foundation for future clinical trials and longer-term microdosing protocols in dogs with separation-related behavioural problems.
Papers cited by this study that are also in Blossom
Anderson, T., Petranker, R., Christopher, A. et al. · Harm Reduction Journal (2019)
Borkel, L. F., Rojas-Hernández, J., Henríquez-Hernández, L. A. et al. · Expert Review of Clinical Pharmacology (2023)
Cameron, L. P., Benson, C. J., Defelice, B. C. et al. · ACS Chemical Neuroscience (2019)
Horsley, R. R., Páleníček, T., Kolin, J. et al. · Behavioural Pharmacology (2018)
This pilot was a single-animal, open-label, observational trial conducted in the subject’s home. The participant was a 13-year-old spayed mixed-breed female dog (13 kg) with a lifelong history of separation-related anxiety. Ethical approval was obtained from the University of Las Palmas de Gran Canaria animal ethics committee and informed owner consent was secured. The trial took place on 10 January 2024 under continuous supervision by a veterinary ethologist and a veterinary toxicologist, with veterinary clinical support available if required. The intervention was a single oral administration of 5 µg 1cP-LSD (half of a 10 µg pellet), disguised in a piece of ham. The investigators note that 1cP-LSD is a lysergamide that hydrolyses to LSD in blood and that its exact pharmacokinetics relative to other analogues are uncertain. Behavioural assessment used a previously validated 17-item separation-anxiety questionnaire producing scores categorised from "no separation anxiety" to "severe separation anxiety"; the dog’s baseline score and subsequent behaviour were recorded. The owner also completed the Non-Romantic Attachment Scale to characterise owner attachment style. During the five-and-a-half-hour observation period the team implemented a pre-planned series of anxiety-provoking stimuli (for example, the owner leaving the house) at set intervals and qualitatively categorised responses as none, moderate, or intense. Observations were video-recorded and the owner was relied upon for primary reports of normality or change. Post-trial follow-up contact was maintained for 24 hours and for seven days thereafter. No blinding, randomisation, or inferential statistical analyses were reported; outcomes were described qualitatively and with selected quantitative scores (e.g. anxiety scale, attachment subscales).
Baseline assessment showed severe separation anxiety: the dog scored 29 on the 17-item anxiety questionnaire. The owner’s attachment-profile scores indicated a fearful-avoidant style with anxious features (reported subscale scores: fearful 9/12, anxious 8/12, avoidant 7/12; secure 4/8). Thirty minutes after ingesting 5 µg 1cP-LSD, the owner reported the dog’s behaviour as ‘‘completely normal’’; the dog interacted with the environment, wagged its tail and appeared docile. At about one hour the animal lay down to sunbathe; at 90 minutes an anxiety-provoking stimulus (owner leaving) initially produced barking and whining consistent with the dog’s typical response. According to the temporal observations, a shift in behaviour occurred from approximately two hours post-administration: the dog became calmer, did not follow the owner when they left, did not vocalise or exhibit typical effusive greeting behaviour on return, and drank water for the first time during the session. At three hours a repeated stimulus elicited minimal barking and the dog remained in place when returned to its spot. By about four hours the dog ate and continued to explore, climb stairs and interact; at five hours she was calm during the owners’ mealtime, a situation that had previously provoked anxiety. The trial concluded at 5.5 hours. No adverse effects were reported during observation or in the 24-hour follow-up: there were no episodes of agitation, aggression, loss of consciousness, vomiting, respiratory distress, or other clinically significant events. The investigators did not observe mydriasis (pupil dilation) or overt signs of a psychedelic experience (stumbling, howling, restlessness, fear). The authors note that the time course resembled human reports for comparable compounds, with a peak effect around 2–3 hours and a return toward baseline from about 5 hours. The analysis presented was descriptive; no inferential statistics or comparator data are reported. The investigators acknowledge that the continuous presence of two unfamiliar observers could have influenced behaviour and that a single-subject design limits generalisability.
Henríquez-Hernández and colleagues interpret this single-case observation as indicating that a single low oral dose of 1cP-LSD was well tolerated in this dog and temporally associated with a reduction in separation-related anxiety behaviours during the five-and-a-half-hour observation window. The authors emphasise that the anxiolytic-like effects appeared transient, with baseline behaviours returning from approximately 4–5 hours after intake, and they propose that a structured microdosing regimen over weeks to months would be required to evaluate cumulative therapeutic benefit, as in human trials. The discussion situates these findings within broader research on classical psychedelics: the investigators draw parallels to serotonergic mechanisms (noting 5-HT2A receptor involvement in humans) while acknowledging that the precise mechanism of action in dogs is unknown. They also consider non-pharmacological influences: the owner’s insecure, fearful-avoidant attachment profile may modulate the animal’s baseline anxiety and could have affected outcomes via bidirectional stress transmission; the presence of observers is also noted as a possible confound. The authors propose that future work should characterise individual animal stressors, behavioural markers (including body language), owner factors, tolerance, and longer-term dosing schedules. Key limitations acknowledged in the paper include the single-subject design, lack of controls or blinding, potential observer effects, and absence of pharmacokinetic data. The investigators recommend controlled clinical trials with larger samples and systematic microdosing protocols to determine safety, efficacy and mechanisms in canines. They also suggest that research in this area could inform questions about animal consciousness and cross-species comparisons of psychedelic effects, while reiterating that mechanistic and ethical issues require further study.
The authors state that, to their knowledge, this is the first reported pilot trial of 1cP-LSD administered with therapeutic intent in a dog. Under the conditions described, a single oral 5 µg dose was considered safe and was associated with a marked, temporally limited reduction in separation-related anxiety behaviours, with peak effects at about 2–3 hours and a gradual return to baseline from around 5 hours. These preliminary findings are presented as justification for conducting larger, controlled clinical studies to evaluate the potential utility of 1cP-LSD microdosing for dogs with separation-related behavioural problems.
Approximately 14-20% of dogs (Canis lupus familiaris) are estimated to experience anxiety. Anxiety inflicts substantial suffering upon the animal and its caregivers, presenting in various manifestations such suggested, there must be a significant environmental influence in the development of canine anxiety. To treat canine anxiety, selective serotonin reuptake inhibitors (SSRIs)-known in human medicine as antidepressants-benzodiazepines-commonly referred to as anxiolytics-and other medications (tricyclic antidepressants or Alpha2 agonists) are used. Similar to human medicine, pharmacological treatments are often unsuccessful. These drugs involve chronic use, narrow safety margins, and can lead to addiction and withdrawal syndrome if abruptly discontinued. Therefore, safe therapeutic alternatives are needed to enhance clinical outcomes, as the reality is that the success of pharmacological treatment, even with ethological support, is limited). Among these new molecules are cannabinoid derivatives (CBD), but currently, their effectiveness for anxiety control in dogs is very limited). In the last decade, psychedelic substances have undergone a powerful resurgence. Despite the lingering social prejudice resulting from discrediting campaigns during the period known as the 'Acid Panic,' these substances have demonstrated significant therapeutic potential, particularly in relation to mental illnesses, specifically depression and anxiety. Moreover, psychedelics are very safe substances that do not induce addiction or leave lasting effects if consumed responsibly and at indicated doses). Despite differences in origin, preparation, and dosage, most of these substances act similarly in the central nervous system (CNS). They all share serotonin as a common denominator, altering its homeostasis through interaction with 5-HT2A receptors. However, knowledge gaps still exist to explain the effects these substances have on individuals, especially regarding the behavioral changes in their users. In the context of psychedelic therapy, recent evidence suggests that set -referred to the mental and emotional state of the individual at the time of psychedelic consumption -and setting -referred to the physical and social environment in which the psychedelic experience takes place -predict psychopathology and wellbeing). Among the variables, the motivation or intention to use psychedelics emerges as a fundamental element for therapeutic success. Given that motivation is a uniquely human trait not transferable to animals, therapeutic studies involving psychedelics in animals lack will and intentionality. Nevertheless, there are documented indigenous practices in the South American continent aimed at enhancing the hunting skills of dogs through the administration of natural psychedelics found in various plants. This suggests that, while the level of consciousness and will in animals may not be comparable to that of the human, it may be sufficient in some species for the effects of certain psychedelic substances to be observed. Lysergic acid diethylamide (LSD) has shown efficacy in treating certain behavioral disorders, such as anxiety and depression, even in microdoses. Microdosing involves the administration of 10-15% of the acute effective dose, ensuring the absence of the psychedelic effects typical of these substances, as well as the absence of measurable physiological effects. Previous studies conducted in rodents have demonstrated that the administration of psychedelics in microdoses has an anxiolytic and antidepressant effect. Although their beneficial effects are not replicated in all cases, such as alcohol addiction, these substances seem to be particularly useful as anxiolytics. Since the serotoninergic system in the canine species is similar to that of humans, the use of this substance could be beneficial in alleviating the anxious states experienced by dogs. The similarities between the two species extend beyond neural physiology. Dogs, like humans, develop behavioral problems such as early-development disorders, affective disorders, personality disorders, and obsessive-compulsive disorders. The aim of this study was to assess the suitability and safety of 1-cyclopropionyl-d-lysergic acid diethylamide (1cp-LSD), a legal LSD analogue, for investigating the behavioral response of a dog subjected to a single microdose of a substance known for its anxiolytic properties in humans. Given the absence of prior research in this specific context, we sought to establish a baseline for understanding canine reactions to this treatment. To our knowledge, it was the first time that this molecule was administered with therapeutic intent in this animal species, and it represents a necessary preliminary step before conducting a clinical trial. Once the effect of a single dose is known, long-term treatment can be safely initiated, allowing us to observe whether there are changes in the anxiety spectrum of dogs with this behavioral disorder. Thus, the present study reports the results and observations related to this pilot trial, and discusses the therapeutic implications of using psychedelic substances for curative purposes in animals.
With great altruism, a 33-year-old woman responded to the pilot program's request to have her dog participate in the study. The patient was a 13-year-old female dog, of mixed breed, and spayed, named Lola. Despite living with the owner for a year, the animal has always been part of the family, exhibiting anxious behavior since birth. Lola's weight on the day of the trial was 13 kg. The animal resides in a single-story house with access to a patio and outdoor gardens belonging to the house. The dog has continuous access to food and water. She coexists with another dog that does not exhibit any anxious behavior. The trial was conducted at the home where the animal and its owner reside, following the design outlined in the clinical trial. According to the dog's medical history, she did not suffer from any pathology that could disqualify her from the trial. Informed consent was obtained from the owner before the test was performed. The animal has never received any medication to control her anxiety. The study has obtained approval from the Animal Experimentation Ethics Committee of the University of Las Palmas de Gran Canaria (Ref No. OEBA_ ULPGC 02/2024). The test was supervised at all times by a veterinary ethologist and a veterinary toxicologist. The assistance of the Veterinary Clinical Hospital of the Faculty of Veterinary Medicine of the University of Las Palmas de Gran Canaria was available in case it was needed.
The animal has had a history of separation related behavioral problems throughout her life. To objectively assess the degree of anxiety in the dog, a validated and previously published scale was utilized. It is a questionnaire consisting of 17 questions that assess anxiety on a scale from 0 to 21 points or more, as follows: 0 to 3 points = No Separation Anxiety; 4 to 8 points = Mild Attachment Disorder (non-clinical); 9 to 15 points = Moderate Separation Anxiety; 16 to 20 points = Marked Separation Anxiety; 21 or more points = Severe Separation Anxiety. The instrument assesses anxious canine behaviors when owners are preparing to leave the house, upon return, and when the dog is alone. It also considers vocalization, barking, salivation, and compulsive behaviors such as selfmutilation or object destruction, both in terms of their presence and the intensity of these anxious behaviors. Once the dog's basal anxiety state was established, the team of veterinarians programmed a series of stimuli that would trigger anxious responses to observe the animal's reactions. These stimuli were selected based on the information provided by the owner about which elements provoke reactions in the dog: moving away from the animal, leaving the house, olfactory stimuli related to food, among others. These stimuli were implemented throughout the test at different time intervals, and were qualitatively categorized as follows: no anxious response, moderate anxious response, or intense anxious response. A correlation between the psychological profiles of pet owners and the behavioral pathologies exhibited by their animals has been reported. In light of the apparent influence of owner attachment style on pet behavior (O, we used an emotional attachment scale that was completed by Lola's owner. The Non-Romantic Attachment Scale is a validated questionnaire consisting of 11 questions aimed to assess the degree of attachment not related to romantic partners of the individual, differentiating between fearful, avoidant, secure, and anxious attachment. Finally, data related to the animal (age, breed, weight…), the living environment (type of house, presence of other animals…), and the owner (age, duration of cohabitation with the animal, and contact information for follow-up) were collected. The questionnaire included two additional questions: (i) Are you clinically diagnosed with anxiety/ depression? and, (ii) Do you take anxiolytics or any medication for anxiety/depression?
1cP-LSD (1-cyclopropionyl-d-lysergic acid diethylamide) is a semi-synthetic psychedelic substance belonging to the class of lysergamides. It is an analogue of LSD and has been available for research since July 2019. Similar to other lysergamides, it is likely that 1cP-LSD interacts with a wide range of monoamine receptors, such as adrenergic and dopamine receptors, in addition to acting as an agonist of serotonin 5-HT receptors. The substance hydrolyzes to LSD through the action of blood carboxylesterases, giving rise to the compound. Therefore, it behaves as a prodrug. However, nowadays it is unclear whether the nature of the 1-acyl substituent leads to differences in pharmacokinetic parameters compared to other semi-synthetic psychedelic substances, including the formation of LSD in vivo. 1cp-LSD was legally acquired through an online supplier. Each pellet contains 10 µg of the active compound and is designed to be cut and dosed at 5 µg (Fig.). Therefore, a total of 5 µg was administered orally to the subject, equivalent to 0.38 µg/kg. Translated to humans, this represents a dose of 30.7 µg (for an 80-kilogram person), slightly exceeding the upper limit of a typical microdosing range (5-25 µg).
The administration of the substance took place on January 10, 2024, at 12:15 PM. 5 µg of 1cP-LSD (half a pellet) was administered, disguised in a piece of ham. The dosage was prepared by the veterinary toxicologist, following the (scheduled absences, specific sounds), everything was done with the prior approval of the animal's owner. The anxiety and emotional attachment questionnaires were administered on that day. After the trial was concluded, communication was maintained with the owner for the remainder of that day and during the following seven days.
The entire experience was documented in a video accessible through this document (available at:). The subject's score on the anxiety scale was 29 points, indicating severe anxiety. Anxious behaviors, including whining, barking, crying, and furniture destruction, were notable when the owners left the house and while they were away. An anxious behavior was reported in terms of effusive greeting when the owners return home, and compulsive following wherever they go within the home context. Extensive biting and scratching on home furniture were also reported when the animal was left alone. There were no reported compulsive urinations or defecations, nor excessive salivation. The analysis of the owner's questionnaire reveals a fearful/avoidant attachment profile with a high anxious component, reporting the following scores: 9 out of 12, 8 out of 12, and 7 out of 12 possible points for fearful, anxious, and avoidant attachment subscales, respectively. The score for secure attachment was the lowest, obtaining 4 out of 8 points. A fearful-avoidant attachment profile with an anxious component suggests an insecure connection, marked by fear of intimacy and simultaneous need for closeness. Thirty minutes post-administration of the substance, Lola's behavior was completely normal, according to her owner's report (Fig.). In this sense, the owner's observations were crucial to complement the observations recorded by the specialized personnel who supervised the test. She interacted with her surroundings, wagging her tail continuously, and exhibited a docile and engaged demeanor. After an hour, the animal lay down to sunbathe, not falling asleep, with the owner not observing anything abnormal. Minutes later, she sought shelter inside the house. Upon observation, she got up without issues and interacted normally. Ninety minutes after drug administration, we subjected Lola to an anxiety stimulus. The owner and the family member left the house, and the dog exhibited typical anxious behavior of barking and whining. Based on the owner's report, the observed behavior was consistent with the typical anxiety's dog response. It should be emphasized that the anxious behavior is particularly evident in the absence of the primary caregiver, notwithstanding the presence of other individuals (the observers, in this particular instance). After manufacturer's recommendations for its handling. According to the owner's report, the dog had consumed a meal approximately 90 min prior to the initiation of treatment. The trial was scheduled at the house where the animal and its owner live: a countryside residence in a rural setting with access to a patio and outdoor gardens belonging to the house. In addition to the owner, there was another family member as well as two members of the research team: a toxicologist and an ethologist, both veterinarians. Given the unfamiliarity of the observers to the animal, a one-hour acclimation period was implemented before drug administration. The dog demonstrated friendly behavior throughout the interaction. The role of the research team was purely observational, with no intervention on the animal beyond a physical examination to evaluate the effect of the substance, primarily mydriasis. The two investigators continuously observed the animal's behavior, working closely with the owner to identify any abnormal behaviors. Both the owner and the family member were present throughout the trial. While stress triggers were indeed explored during the trial owner returned. At that moment, the animal did not show signs associated with its anxious behavior, such as whining, barking, or effusive greetings. The animal ate after 4 h from the start of the experience. She was observed going up and down stairs, exploring, wagging her tail, and interacting with the environment. No anxious reaction was observed to stimuli such as the owners being in the kitchen preparing food. Abdominal movement associated with breathing was detected, corresponding to a whimper that did not fully manifest. No dyspnea or any adverse effects were observed. The animal did not sleep at any point. Lola remained calm while her owners ate. This occurred 5 h after administration. No anxious behaviors related to the owners' mealtime, which frequently happened, were observed. After 5.5 h, the pilot trial was concluded (Fig.) without any adverse effects on the animal: growls or barks indicative of an altered emotional state, aggressive behaviors, loss of consciousness, or others. Despite the slightly higher dose than that typically used for microdosing, the animal did not show signs of having had psychedelic experience (stumbling, howling, restlessness, fear), not even at a physical level (mydriasis). Consistent communication was maintained with the animal's owner for the following 24 h, ensuring that cognitive recovery was ongoing and no veterinary intervention was required. No clinically significant events were reported. To assess the treatment's effect on anxiety modulation, it's essential to establish a continuous microdosing protocol over time (1-3 months), akin to human trials, which will be explored in a clinical trial. a few minutes, Lola greeted them warmly, although they reported it might have been 'less than usual.' Minutes later, the owners went to another part of the house. They expected the animal to follow them, as it consistently exhibited that anxious behavior, something that was recorded in the anxiety questionnaire. However, the animal did not display such behavior. She did not even draw attention from the owners through barking or whining. Lola drank water for the first time at that point. The owners expressed surprise at this behavior. After two hours, exhibiting a temporal pattern of the effect similar to that observed in humans exposed to this substance, Lola appeared calm (Fig.). She climbed into the chair by herself. At that moment, specific music for the psychedelic experience was played. The animal appeared relaxed and showed no signs of discomfort or aversion to the sound. After a few minutes, we repeated the anxious stimulus: the owner left the house. The patient did not follow her, did not bark or vocalize. Minutes later, she came back. The dog recognized her, wagging her tail, and greeted her calmly without leaving the couch. Lola's behavior had changed, something very evident to her owner, who expressed it. The researchers present at the trial did not observe mydriasis, which is one of the most evident signs of an LSD toxic effect. Three hours after the administration, the anxious stimulus was repeated (Fig.). After leaving the house, the dog left the couch and barked minimally at the door. We returned her to her spot, and she stayed there for a few minutes until the Fig.Gantt chart depicting the temporal progression of the experience. Green represents no anxious response, orange represents moderate anxious response, and red represents intense anxious responses to administered stimuli in this context. For this reason, further studies should implement a specific microdosing protocol to assess its (potential) cumulative therapeutic. effect, as has been done in human studies. The observations of patient 0 being less impulsive, more relaxed, and less prone to fear or anxiety after administration of 1cP-LSD suggest an alteration in emotion processing and an attentional shift away from stressors. This result is consistent with previous animal trials with LSD that report symptoms of sedation, depression, excitation, changes in behaviour and hallucinations). Other alterations have been reported in dogs that are regularly administered with several psychedelics in order to improve their hunting abilities in the context of indigenous practices. Serotonin agonists like ergot-like alkaloids, N,N-Dimethyltryptamine, psilocybin/ psilocin and 5-meth-N, N-dimethyltryptamine which carry hallucinogenic effects in both human and animal models, are supposedly associated to the increase of hunting effectiveness in both humans and animals. This is consistent with the evidence of psilocybin triggering thalamic down-regulation and frontal hypermetabolism, which has been suggested to induce drugdependent synaesthesia. This neurological condition is defined as the coupling of two or more bodily connected senses, induced by the reduction of sensory feedback pathways, mechanism which might be a causal factor for altered consciousness, manifested in the form of enhanced olfactory, auditory and visual perception. Due to the shared characteristics of these alkaloids with 1cP-LSD, alterations in perception such as synaesthesia and sensory enhancement should not be discarded for patient 0. Therefore, we consider that further research into the psychoactive effects of 1cP-LSD microdoses should be further explored in a clinical trial with a larger sample. Whereas the exact mechanism by which 1cP-LSD reduces anxiety is unknown, parallels from human studies with similar psychedelic substances could be drawn. In humans, LSD, psilocybin and other classic psychedelics have been demonstrated to act on serotonin 2 A receptors (5-HT 2A ), which play a significant role in mood and anxiety regulation. Further clinical trials could show how similar mechanisms might be at play in dogs and other mammals, and draw parallels between human and non-human animals regarding attentional and emotional regulation, memory access and memory reconsolidation, among other things. Additionally, our case study also suggests that research on animal altered experiences could shed light on fundamental aspects of animal consciousness. Understanding how such substances influence the canine cognition and behaviour could offer insights into the broader field of animal In summary, this pilot study has shown that the tested dose of 1cp-LSD is safe for dogs: no adverse effects were observed (agitation, mydriasis, loss of consciousness, vomiting, confusion, or panic attacks) and it produced the expected effect compared to what occurs in human microdosing (tranquility, relaxation, interaction with the environment, and a similar temporal development around 5-6 h).
In this study, 5 µg of 1cp-LSD was administered to a 13-year-old, 13-kilogram mixed-breed dog named Lola, with a history of severe anxiety, according to the canine anxiety assessment scales used. As reported above, specific symptoms of anxiety related to separation from her owner were mitigated, such as reduced barking, crying, and overall distress. Also, symptoms of separation anxiety and anxiety caused by exposure to specific stressors like the sound of doorbells and machinery were not present during the experience. Nevertheless, the continuous presence of two observers during the treatment could have influenced the animal's behaviour. To mitigate this potential bias, the owner's report of the animal's behaviour was crucial for drawing objective conclusions from the observations. The present study suggests that further studies with 1cP-LSD for anxiety reduction in dogs are warranted. Given the established relationship between human and animal behaviour in the context of pets, we also believe that further studies should not only clearly identify animal-individual specific stressors (e.g. sounds), changes in behaviour before, during and after treatment, qualitative observations (e.g. body language, interaction with owner and other animals) and drug tolerance; but also the potential effect of attachment to ownersand owner to pet stress transmission). In the present study, dog's owner exhibited a fearful-avoidant profile with an anxious component, suggesting an insecure connection characterized by a fear of intimacy and a simultaneous need for closeness. The potential influence of this on the animal's behaviour needs further investigation. It has been reported that owners may attribute improvements in their own symptomatology to their pet's condition. Conversely, transient elevations in owner anxiety can significantly impact canine anxiety levels (O. Therefore, future studies should consider the presence of behavioural disturbances in owners of dogs with separation related behavioral problems. As shown in the results, the anxiolytic effects of the substance were temporary as baseline behaviour and symptoms returned 4-5 h after the intake. This observation is crucial for understanding the duration of 1cP-LSD's effectiveness Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit. experience, bridging the gap between neurophysiological changes, observable behavioural outcomes, and the difficult topic of animal consciousness. Previous studies have discussed the emergence of consciousness in the evolutionary timeline proposing the use of general anaesthesia to study the resulting emergence process of consciousness as a model to assess the development across species. These approaches delve into the role of cortical and subcortical regions involved in the phenomenon of consciousness in non-human species, which tie in with our case by providing a broader context on how consciousness and sensory perception are interconnected across species. A model based on psychedelics could be a different approach to explore neural correlates which underlie consciousness emergence in humans and non-human animals as well as fundamental phenomenological aspects of conscious experience shared by different species.
According to our knowledge, this is the first time that a pilot trial of this nature has been conducted and reported in the canine species. The 1cp-LSD proved to be safe under these conditions (appropriate setting) and exerted the desired effect on the animal's behaviour, significantly reducing the patient's anxiety. The duration of the experience was comparable to that reported in humans, with the peak effect observed at 2-3 h and a gradual return to baseline from 5 h onwards. These findings will allow for the safe conduct of future studies investigating the potential utility of 1cp-LSD microdosing for the treatment of dogs with separation related behavioral problems.
Create a free account to open full-text PDFs.
Neil, J. C., Nutt, D. J. · Journal of Psychopharmacology (2022)
Kwan, A. C., Olson, D. E., Preller, K. H. et al. · Nature Medicine (2022)
Meinhardt, M. W., Güngör, C., Skorodumov, I. et al. · Neuropsychopharmacology (2020)